Vavricka, Stephan R; Galván Hernández, José Alberto; Dawson, Heather; Soltermann, Alex; Biedermann, Luc; Scharl, Michael; Schoepfer, Alain M; Rogler, Gerhard; Prinz Vavricka, Mareike B; Terracciano, Luigi; Navarini, Alexander; Zlobec, Inti; Lugli, Alessandro; Greuter, Thomas (2018). Expression Patterns of TNFα, MAdCAM1 and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. Journal of Crohn's & colitis, 12(3), pp. 347-354. Oxford University Press 10.1093/ecco-jcc/jjx158
|
Text
jjx158.pdf - Published Version Available under License Publisher holds Copyright. Download (3MB) | Preview |
Background
Pathogenesis of cutaneous extraintestinal manifestations (EIM) in inflammatory bowel disease (IBD) remains elusive. Efficacy of anti-TNF agents suggests TNF-dependent mechanisms. The role of other biologics such as anti-integrins or JAK-inhibitors is not yet clear.
Methods
We performed immunohistochemistry for TNFα, NFκB, STAT1/STAT3, MAdCAM1, CD20/68, caspase 3/9, IFNγ, Hsp-27/70 on 240 intestinal (55 controls, 185 IBD) and 64 skin biopsies (11 controls, 18 Erythema nodosum (EN), 13 Pyoderma gangenosum (PG), 22 psoriasis). A semiquantitative score (0-100%) was used for evaluation.
Results
TNFα was upregulated in intestinal biopsies from active Crohn`s disease (CD) vs. controls (36.2 vs. 12.1, p<0.001), but not ulcerative colitis (UC: 17.9). NFκB however was upregulated in intestinal biopsies from both active CD and UC (43.2 and 34.5 vs. 21.8, p<0.001 and p=0.017). TNFα and NFκB were overexpressed in skin biopsies from EN, PG and psoriasis. No MAdCAM1 overexpression was seen in skin tissues, while it was upregulated in active UC vs. controls (57.5 vs. 35.4, p=0.003). STAT3 was overexpressed in the intestinal mucosa of active and non-active IBD, while a similar upregulation was seen in skin biopsies from EN (84.7 vs. 22.3, p<0.001) and PG (60.5 vs. 22.3, p=0.011), but not in psoriasis. Caspase 3 and CD68 overexpression in skin biopsies distinguished EN/PG from psoriasis and controls.
Conclusions
Upregulation of TNFα/NFκB in EN and PG is compatible with the efficacy of anti-TNF in EIM management. Data on overexpressed STAT3, but not MAdCAM1 support a rationale for JAK-inhibitors in EN and PG, while questioning the role of vedolizumab.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Service Sector > Institute of Pathology > Translational Research Unit 04 Faculty of Medicine > Service Sector > Institute of Pathology 04 Faculty of Medicine > Service Sector > Institute of Pathology > Clinical Pathology |
UniBE Contributor: |
Galván Hernández, José Alberto, Dawson, Heather, Zlobec, Inti, Lugli, Alessandro |
Subjects: |
500 Science > 570 Life sciences; biology 600 Technology > 610 Medicine & health |
ISSN: |
1873-9946 |
Publisher: |
Oxford University Press |
Language: |
English |
Submitter: |
Inti Zlobec |
Date Deposited: |
31 Jan 2018 16:14 |
Last Modified: |
23 Nov 2023 16:28 |
Publisher DOI: |
10.1093/ecco-jcc/jjx158 |
PubMed ID: |
29182760 |
Uncontrolled Keywords: |
JAK-inhibitor anti-TNF anti-integrins extraintestinal manifestations immunohistochemistry microarray |
BORIS DOI: |
10.7892/boris.110619 |
URI: |
https://boris.unibe.ch/id/eprint/110619 |